Monoclonal antibody immunotherapy for non-Hodgkin malignant lymphoma

Therapeutic options: There is a need in the management of non-Hodgkin's lym phoma (NHL) for tumor-targeted therapy. immunotherapy with monoclonal antib odies can be used to reach this goal. These treatments have however often p roduced disappointing efficacy and so have not been broadly applicable to p atients. Modified monoclonal antibodies: Technological advances have been used to al ter mouse monoclonal antibodies genetically, leading to the development of mouse/human chimeric or humanized antibodies with demonstrated advantages o f reduced immunogenicity and enhanced ability to interact with human effect or cells. Initial phase I/II trials of monoclonal antibodies for relapse or refractory NHL, especially with chimeric anti-CD20 rituximab, demonstrated encouraging results. Further assessment: Randomized trials are now necessary to compare these ag ents with standard regimens and to determine their optimal use.